Redeye initiates coverage of Magle Chemoswed, a hybrid medtech/biotech company with a diverse array of revenue streams. Building on the foundations of its robust CDMO business, Magle is on the brink of commercial take-off with its portfolio of innovative medtech products. With its proprietary DSM technology platform as the focal point for the business, we see an ample growth story in the making with limited downside risk.